Comparing Fluoropharma Medical (FPMI) & Immunomedics (IMMU)

Fluoropharma Medical (OTCMKTS:FPMI) and Immunomedics (NASDAQ:IMMU) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Valuation & Earnings

This table compares Fluoropharma Medical and Immunomedics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fluoropharma Medical N/A N/A -$2.04 million N/A N/A
Immunomedics $2.16 million 1,545.67 -$273.83 million ($1.03) -17.06

Fluoropharma Medical has higher earnings, but lower revenue than Immunomedics.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Fluoropharma Medical and Immunomedics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fluoropharma Medical 0 0 0 0 N/A
Immunomedics 0 0 7 0 3.00

Immunomedics has a consensus target price of $38.43, suggesting a potential upside of 118.72%. Given Immunomedics’ higher probable upside, analysts clearly believe Immunomedics is more favorable than Fluoropharma Medical.

Institutional & Insider Ownership

0.5% of Fluoropharma Medical shares are owned by institutional investors. Comparatively, 77.3% of Immunomedics shares are owned by institutional investors. 36.9% of Fluoropharma Medical shares are owned by insiders. Comparatively, 14.8% of Immunomedics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


This table compares Fluoropharma Medical and Immunomedics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fluoropharma Medical N/A N/A N/A
Immunomedics -12,701.21% -85.57% -39.05%

Volatility & Risk

Fluoropharma Medical has a beta of 3.15, meaning that its share price is 215% more volatile than the S&P 500. Comparatively, Immunomedics has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500.


Fluoropharma Medical beats Immunomedics on 6 of the 10 factors compared between the two stocks.

Fluoropharma Medical Company Profile

FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.

Immunomedics Company Profile

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune, to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with The Bayer Group for the development of epratuzumab; clinical and preclinical collaborations with academic cancer institutions, identifying new cancer indications for sacituzumab govitecan and the biology of the Trop-2 antigen; and research collaboration with the Memorial Sloan Kettering Cancer Center to investigate Sacituzumab Govitecan and Labetuzumab Govitecan in preclinical cancer models. Immunomedics, Inc. has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Receive News & Ratings for Fluoropharma Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluoropharma Medical and related companies with's FREE daily email newsletter.

Leave a Reply